Parvovirus B19 and erosive polyarthritis

Tyndall, A; Jelk, W; Hirsch, Hans H.

doi:10.1016/s0140-6736(94)92725-1

Cited by 43 publications

(13 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Evidence favouring this link comes from studies ®nding high prevalence of B19 antibodies or con®rmed recent B19 infection, or both, in patients with RA [7], JRA [6] or erosive polyarthritis [27].…”

Section: Discussionmentioning

confidence: 99%

Lymphocyte recognition of human parvovirus B19 non-structural (NS1) protein: associations with occurrence of acute and chronic arthropathy?

Mitchell

Leong

Rosenke

2001

Journal of Medical Microbiology

View full text Add to dashboard Cite

Immune recognition of recombinant parvovirus B19 non-structural (rNS1) protein was studied by immunoblot and lymphoproliferative assays in blood from the following B19 seropositive groups: B19 infected (n 14), B19 exposed but non-infected (n 16), other illness with rash (n 3), chronic arthropathy of unknown aetiology (n 4) and healthy controls (n 7). Sera from 11 B19 seronegative subjects were also studied. Sera collected at initial diagnosis or at the time of accidental B19 exposure in pregnancy were tested for NS1 antibody and evidence of B19 DNA by nested PCR. Follow-up specimens were obtained 3±12 months later for serological, PCR and proliferation studies. B19 DNA was detected sporadically in early specimens and in one follow-up specimen from a subject who developed chronic arthropathy after B19 infection. There was no correlation with development of arthropathy. NS1-speci®c IgG was detected in early sera from B19-infected and exposed subjects but to a lesser degree in follow-up specimens, and in only one healthy control serum. No correlation with the presence of NS1-speci®c antibodies was found with development of acute or chronic arthropathy. Although lymphocyte proliferation in response to stimulation with rNS1 in vitro occurred at a higher frequency in patients who developed acute and chronic joint manifestations after B19 infection, suggesting an association with this outcome, NS1-reactive lymphocytes were also found in three B19 seronegative patients, two of whom had recently been exposed to B19 but had no illness. Hence, immune recognition of NS1 may be more indicative of recent infection with, or exposure to, parvovirus B19 than associated with development of arthropathy as previously reported.

show abstract

Section: Discussionmentioning

confidence: 99%

Lymphocyte recognition of human parvovirus B19 non-structural (NS1) protein: associations with occurrence of acute and chronic arthropathy?

Mitchell

Leong

Rosenke

2001

Journal of Medical Microbiology

View full text Add to dashboard Cite

show abstract

“…About 75 % of these patients have an associated rash and ,20 % have the typical 'slapped cheeks' facial exanthem. B19 has been proposed as the causative agent of arthritic conditions that exhibit similar symptomologies to those found in rheumatoid arthritis (RA), juvenile RA and erosive polyarthritis, as recent B19 infection and high levels of B19 antibodies have been evident in many of these patients (White et al, 1985;Nocton et al, 1993;Mimori et al, 1994;Tyndall et al, 1994). It has been suggested that B19-associated arthritis is related to certain human leukocyte antigen (HLA) haplotypes of patients, with individuals of either HLA DR4 or B27 being most susceptible (Klouda et al, 1986;Jawad, 1993); however, it is unclear how B19 causes symptoms that are associated with arthritis.…”

Section: Arthropathymentioning

confidence: 99%

Advances in the biology, diagnosis and host–pathogen interactions of parvovirus B19

Corcoran

Doyle

2004

Journal of Medical Microbiology

153

103

View full text Add to dashboard Cite

Increased recognition of parvovirus B19 (B19), an erythrovirus, as a significant human pathogen that causes fetal loss and severe disease in immunocompromised patients has resulted in intensive efforts to understand the pathogenesis of B19-related disease, to improve diagnostic strategy that is deployed to detect B19 infection and blood-product contamination and, finally, to elucidate the nature of the cellular immune response that is elicited by the virus in diverse patient cohorts. It is becoming clear that at least three related erythrovirus strains (B19, A6/K71 and V9) are circulating in the general population and that viral entry into target cells is mediated by an expanding range of cellular receptors, including P antigen and â-integrins. Persistent infection by B19 is emerging as a contributory factor in autoimmune disease, a hypothesis that is constrained by the detection of B19 in the skin of apparently healthy individuals. B19 infection during pregnancy may account for thousands of incidences of fetal loss per annum in Europe, North America and beyond, yet there is currently only minimal screening of pregnant women to assess serological status, and thereby risk of infection, upon becoming pregnant. Whilst major advances in diagnosis of B19 infection have taken place, including standardization of serological and DNA-based detection methodologies, blood donations that are targeted at high-risk groups are only beginning to be screened for B19 IgG and DNA as a means of minimizing exposure of at-risk patients to the virus. It is now firmly established that a Th1-mediated cellular immune response is mounted in immunocompetent individuals, a finding that should contribute to the development of an effective vaccine to prevent B19 infection in selected high-risk groups, including sickle-cell anaemics. Parvovirus B19In 1975, Yvonne Cossart discovered what was to become known as human parvovirus B19 (B19) (Cossart et al., 1975). B19 was first associated with disease in 1981, when it was linked to an aplastic crisis in a patient with sickle-cell disease. It has since been shown to cause erythema infectiosum (EI) (fifth disease of childhood), spontaneous abortion and some forms of acute arthritis (Anderson et al., 1983; Kinney et al., 1988;Woolf & Cohen, 1995).B19 is a small, non-enveloped, ssDNA virus and, like all parvoviruses, the capsid proteins are arranged with icosahedral symmetry. B19 is 20-25 nm in diameter and has a genome of 5 . 6 kb (Clewley, 1984;Cotmore & Tattersall, 1984). The B19 capsid consists of an 83 kDa minor structural protein, VP1, and a 5 kDa major structural protein, VP2. VP2 makes up about 95 % of the total capsid, with VP1 accounting for the remaining 5 % . The sequences of the two proteins are collinear, with VP2 being identical to the carboxyl-terminus of VP1; however, VP1 comprises an additional 227 aa domain that is unique to the amino-terminal (Fig. 1). To the left of these sequences on the B19 genome is the ORF for a non-structural protein, NS1, which encodes a protein product of 7...

show abstract

“…Yet, other studies have found weaker or no associations with chronic arthritis [Hajeer et al, 1994;Nikkari et al, 1994;Kerr et al, 1995;Speyer et al, 1998;Bateman et al, 1999], early inflammatory polyarthritis [Harrison et al, 1998], or transient synovitis [Lockhart et al, 1999] and only rarely, has radiographic evidence of erosive polyarthritis been available [Tyndall et al, 1994]. Much of the evidence in support of involvement of B19 infection in chronic arthritis has come from serologic studies showing a higher than normal preponderance of B19-specific IgG antibodies in RA [Mimori et al, 1994] or JRA [Nocton et al, 1993] patients.…”

Section: Association Of Parvovirus B19 Infection With Chronic Musculomentioning

confidence: 99%

Parvovirus B19 nonstructural (NS1) protein as a transactivator of interleukin‐6 synthesis: Common pathway in inflammatory sequelae of human parvovirus infections?

Mitchell

2002

Journal of Medical Virology

View full text Add to dashboard Cite

This review focuses on the role that human parvovirus B19 nonstructural (NS1) protein as a transactivator of the proinflammatory cytokine, interleukin-6 (IL-6), might play in triggering the multiparametric inflammatory outcomes of B19 infection. Parvovirus B19 is a ubiquitous virus, and it is often expressed during conditions of immunodepression including that induced by long-term chemotherapy, viral infection (HIV, HTLV-1), or genetic immunodeficiency disorders. Through NS1 expression, B19 may contribute to the immune dysregulation associated with these disorders, or serve as a cofactor in enhancing retroviral replication. Hence, NS1 transactivation of proinflammatory cytokine promoters such as IL-6 may be pivotal in triggering the various inflammatory and autoimmune disorders that have been linked to parvovirus B19 infections.

show abstract

Parvovirus B19 and erosive polyarthritis

Cited by 43 publications

References 2 publications

Lymphocyte recognition of human parvovirus B19 non-structural (NS1) protein: associations with occurrence of acute and chronic arthropathy?

Lymphocyte recognition of human parvovirus B19 non-structural (NS1) protein: associations with occurrence of acute and chronic arthropathy?

Advances in the biology, diagnosis and host–pathogen interactions of parvovirus B19

Parvovirus B19 nonstructural (NS1) protein as a transactivator of interleukin‐6 synthesis: Common pathway in inflammatory sequelae of human parvovirus infections?

Contact Info

Product

Resources

About